Printer Friendly

ALPHA-BETA TECHNOLOGY REPORTS EARLY CLINICAL FINDINGS WITH BETAFECTIN AT INTERNATIONAL BIOLOGICAL RESPONSE MODIFIERS CONGRESS

 WORCESTER, Mass., Feb. 1 /PRNewswire/ -- Scientists at Alpha-Beta Technology, Inc. (NASDAQ: ABTI) reported encouraging preliminary results of the first Phase II clinical trial with Betafectin(tm), its receptor- targeted carbohydrate, for the treatment and prevention of infections in patients undergoing major chest or abdominal surgery. The company presented the initial Phase II data, along with studies of Betafectin's chemical and biological properties, on Saturday, Jan. 30, at the Second International Congress on Biological Response Modifiers in San Diego.
 The Phase II study was a randomized open label trial involving 30 surgery patients who received either Betafectin or placebo in addition to standard prophylactic treatment. The trial was designed to assess Betafectin's safety profile in surgery patients and provide preliminary indications of efficacy. Despite the use of antibiotics, the post- surgical infection rate in high-risk surgical patients is estimated to exceed 25 percent and is related to increased morbidity and patient treatment costs. For example, there are an estimated 920,000 post- operative wound infections in the United States each year.
 "While based on a relatively small number of patients, the study supports our hypothesis that Betafectin can reduce the incidence and severity of infection in this high-risk patient population," commented Dr. Spiros Jamas, president and chief executive officer of Alpha-Beta. "There were considerably fewer infections in the Betafectin group compared with the placebo group. The initial Phase II results are also consistent with data from preclinical studies and from our Phase I trial in healthy volunteers. Specifically, Betafectin was well tolerated in these patients and there was increased white blood cell infection- fighting activity in patients receiving Betafectin.
 "We are very encouraged at this juncture and will continue to build on this information," Dr. Jamas noted. "We will refine these results through additional analyses and we look forward to the results of ongoing and additional Phase II trials." The company is conducting an additional study in surgery patients and expects to publish the results of these studies at a later date.
 Alpha-Beta Technology, Inc. is developing proprietary carbohydrate- based products for the health care industry through the application of carbohydrate engineering. The company's major products in development include Betafectin for the treatment and prevention of infections; Cholestran(tm) for the treatment and prevention of cardiovascular disease; and Fibercel(tm), a fat substitute. Alpha-Beta's headquarters, laboratory and pilot production facilities are located in Worcester, Mass.
 -0- 2/1/93
 /CONTACT: Spiros Jamas, Sc.D., president and CEO of Alpha-Beta Technology, Inc., 508-798-6900; or Robert Gottlieb, vice president, Feinstein Partners Inc., 617-577-8110, for Alpha-Beta Technology/
 (ABTI)


CO: Alpha-Beta Technology, Inc. ST: Massachusetts IN: MTC SU:

CH-DD -- NE002 -- 1131 02/01/93 08:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 1993
Words:442
Previous Article:UNITED HEALTHCARE COMPLETES PURCHASE OF WESTERN OHIO HEALTH CARE
Next Article:NETWORK WORLD, DATAQUEST SURVEY SHOWS NETWORK SERVICE AND SUPPORT THE TOP BUYING CRITERIA
Topics:


Related Articles
ALPHA-BETA TECHNOLOGY BEGINS BETAFECTIN PHASE I CLINICAL TRIALS; FIRST OF NEW ENGINEERED CARBOHYDRATE PHARMACEUTICALS TO ENTER HUMAN STUDIES
ALPHA-BETA TECHNOLOGY, INC. REPORTS YEAR-END FINANCIAL RESULTS
ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 FIRST QUARTER RESULTS
ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 SECOND QUARTER RESULTS
PRECLINICAL DATA SUPPORTING BETAFECTIN PGG-GLUCAN HEMATOPOIETIC ACTIVITY REPORTED AT BIOLOGICAL RESPONSE MODIFIERS CONFERENCE
ALPHA-BETA ANNOUNCES DISCOVERY OF NOVEL RECEPTOR FOR PRIMING OF HUMAN IMMUNE CELL DEFENSES
Antegren(R) (natalizumab) Phase II Data Show Promising Results in Crohn's Disease.
Biogen Scientists Identify Presence of Key Genes in Kidney Fibrosis, Pointing To Possible New Therapeutic Approaches.
Biogen and Elan Present Promising Data for Antegren(R) (Natalizumab) in Multiple Sclerosis at Ectrims Congress.
Genencor Scientists Show Reduced Immunogenicity of Modified Interferon-Beta Protein.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters